Niraparib-Bevacizumab Combo Improves Clinical Outcomes in Recurrent Ovarian Cancer

The combination use of niraparib plus bevacizumab significantly improved clinical outcomes, compared with niraparib alone, in patients with recurrent ovarian cancer.

Source: CancerNetwork - June 5, 2020 Category: Cancer & Oncology Authors: Audrey Sternberg Source Type: news